All PlansPrior AuthMedium impact
Denosumab Products: (Xgeva®); Denosumab-kyqq (Aukelso™); Denosumab-nxxp (Bilprevda®); Denosumab-bnht (Bomyntra®); Denosumab-bmwo Osenvelt®); Denosumab-bbdz (Wyost®); Denosumab-dssb (Xbryk™), Denosumab-qbde (Xtrenbo™
BCBS Tennessee·Oncology, Hematology, Endocrinology +1 more·Medical Policy
Effective date
Jun 30, 2026
We identified it
Jun 17, 2026
Summary
New comprehensive medical policy for denosumab products (Xgeva and 7 biosimilars) establishes coverage criteria, authorization requirements, and quantity limits for bone-related oncology and systemic mastocytosis treatments. The policy covers FDA-approved indications including prevention of skeletal events in multiple myeloma/bone metastases, giant cell tumor treatment, and hypercalcemia of malignancy.
Action Required
Before June 30, 2026: Billing team must implement prior authorization requirements for all denosumab products (Xgeva, Aukelso, Bilprevda, Bomyntra, Osenvelt, Wyost, Xbryk, Xtrenbo). Update billing system to enforce quantity limits: 120mg every 4 weeks for most indications, 60mg every 6 months for systemic mastocytosis, and special dosing for giant cell tumor/hypercalcemia (120mg on days 1, 8, 15 first month, then every 4 weeks). Configure authorization periods: 12 months for most indications, 2 months for hypercalcemia of malignancy. Ensure documentation requirements for medical necessity are captured.